Clinical applications of platelet-rich plasma in patellar tendinopathy.
D U JeongC-R LeeJ H LeeJ PakL-W KangB C JeongSang-Hee LeePublished in: BioMed research international (2014)
Platelet-rich plasma (PRP), a blood derivative with high concentrations of platelets, has been found to have high levels of autologous growth factors (GFs), such as transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), fibroblastic growth factor (FGF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). These GFs and other biological active proteins of PRP can promote tissue healing through the regulation of fibrosis and angiogenesis. Moreover, PRP is considered to be safe due to its autologous nature and long-term usage without any reported major complications. Therefore, PRP therapy could be an option in treating overused tendon damage such as chronic tendinopathy. Here, we present a systematic review highlighting the clinical effectiveness of PRP injection therapy in patellar tendinopathy, which is a major cause of athletes to retire from their respective careers.
Keyphrases
- platelet rich plasma
- growth factor
- vascular endothelial growth factor
- transforming growth factor
- endothelial cells
- epithelial mesenchymal transition
- total knee arthroplasty
- anterior cruciate ligament reconstruction
- randomized controlled trial
- systematic review
- oxidative stress
- risk factors
- stem cells
- wound healing
- vascular smooth muscle cells
- bone marrow
- anterior cruciate ligament
- ultrasound guided
- drug induced